Cytoplasmic vs Nuclear Delivery of RNA Therapeutics: What’s the Difference?
RNA therapeutics, including siRNA, antisense oligonucleotides, and mRNA, require precise intracellular delivery to exert their biological effects. The location of delivery—cytoplasm versus nucleus—plays a crucial role in determining the mechanism of action, efficiency, and potential applications of these molecules.
Most siRNA therapeutics function in the cytoplasm, where they engage the RNA-induced silencing complex (RISC) to mediate the degradation of target messenger RNA (mRNA). Efficient cytoplasmic delivery ensures that siRNA molecules reach their site of action without degradation, enabling potent and specific gene silencing. The cytoplasm contains the RNAi machinery, and siRNAs must avoid entrapment in endosomes or lysosomes to be functional. Delivery strategies often focus on optimizing endosomal escape and protecting RNA from nucleases.
In contrast, certain RNA therapeutics require nuclear delivery to target pre-mRNA or influence gene transcription. Antisense oligonucleotides that modulate splicing or long non-coding RNAs involved in epigenetic regulation typically act within the nucleus. Nuclear delivery presents additional challenges because the RNA molecules must traverse the nuclear envelope, often relying on nuclear localization signals or transport mechanisms. This compartmentalization also affects dosing, stability, and off-target effects.
Understanding the distinct pathways and barriers for cytoplasmic versus nuclear delivery informs the design of vectors, chemical modifications, and administration routes. While cytoplasmic delivery remains the focus of most siRNA applications, advances in nuclear targeting expand the therapeutic scope of RNA molecules to include gene regulation at the transcriptional and splicing levels.
References: Altogen.com Altogenlabs.com